Clinical trials: Magnetic Resonance Imaging Contrast Agents
Contrast Enhancement in Magnetic Resonance Imaging, Children
A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)
Researchers are looking for a better way to help children under the age of 18 with any known or suspected problems scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
- Trial name
- NCT05915026
- Testing
- Gadoquatrane (BAY1747846)
- Where
- 34 sites in United States, Argentina and 8 more
- Volunteers
- 105 people
- Sponsor
- Bayer
Central Nervous System Diseases
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.
- Trial name
- NCT00395460
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Magnevist
- Where
- 4 sites in China
- Volunteers
- 147 people
- Sponsor
- Bayer
Rotator Cuff Tear, Labral Tear
Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases
The goal of this Phase 3 clinical trial is to evaluate whether MR arthrography enhanced with NEMO-103 injection (NEMO-103 Inj.) provides superior diagnostic imaging quality compared to unenhanced MRI in patients with known or…
- Conditions
- Rotator Cuff Tear, Labral Tear, Rotator Cuff Tendinosis, Rotator Cuff Tendonitis
- Trial name
- NCT07057037
- Testing
- NEMO-103 Injection
- Where
- 8 sites in South Korea
- Volunteers
- 85 people
- Sponsor
- Inventera Inc.
Peripheral Vascular Disease
Crossover Study With MultiHance vs a Comparator for Peripheral MRA
This is a double blind crossover study designed to compare two different gadolinium products given at the same dose to patients undergoing MRA assessment of lower legs for the evaluation of peripheral steno-occlusive disease.
- Trial name
- NCT00408083
- Testing
- MultiHance, Magnevist
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Bracco Diagnostics, Inc
Peripheral Vascular Diseases
Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease
The particular aim of this study is the comparison of the diagnostic results of MRA images upon application of Vasovist (gadofosveset), a contrast agent not yet available on the market, with the MRA images upon application of a…
- Trial name
- NCT00296855
- Testing
- Vasovist (BAY86-5283, MS-325)
- Where
- 26 sites in Argentina, Austria and 4 more
- Volunteers
- 261 people
- Sponsor
- Bayer
Magnetic Resonance Imaging (MRI)
Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination
The purpose of this study is to prospectively collect data on the pattern of use for gadolinium-based contrast agents (GBCAs) in real-life setting with special reference to Clariscan after its commercial launch in Europe and in…
- Trial name
- NCT03455283
- Testing
- Clariscan, Gadolinium-Based Contrast Agents
- Where
- 2 sites in Germany, Norway
- Volunteers
- 2,118 people
- Sponsor
- GE Healthcare
Brain Diseases, Spinal Cord Diseases
Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine.
- Trial name
- NCT00862459
- Testing
- Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
- Where
- 27 sites in United States, Argentina and 2 more
- Volunteers
- 237 people
- Sponsor
- Bayer
Cardiovascular Abnormalities
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the aortic arch and cerebral branches.
- Trial name
- NCT00310609
- Testing
- Gadopentetate dimeglumine (Magnevist)
- Volunteers
- 123 people
- Sponsor
- Bayer
Breast Cancer
Multihance Versus Magnevist in Breast MRI
To show if one MRI contrast agent is better than another one in the diagnosis of malignant breast lesions compared to histopathology
- Trial name
- DETECT (NCT00486473)
- Testing
- Multihance, Magnevist
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Bracco Diagnostics, Inc
Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Researchers are looking for a better way to help people with any known or suspected problems (except brain or spinal cord-related problems) scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
- Trial name
- Quanti OBR (NCT05915728)
- Testing
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine
- Where
- 85 sites in United States, Argentina and 14 more
- Volunteers
- 410 people
- Sponsor
- Bayer
Amyotrophic Lateral Sclerosis
Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety, tolerability, and feasibility of Blood-Brain Barrier (BBB) opening using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent…
- Trial name
- NCT03321487
- Testing
- Blood-Brain Barrier opening with MRgFUS
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- InSightec
Contrast Enhancement in Magnetic Resonance Imaging
A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting
This is an observational study, in which data associated with the wastage with the use of Gadavist single-dose vials, as compared to the wastage associated with the use of the Gadavist imaging bulk packages (IBP) used for…
- Trial name
- NCT05350189
- Testing
- Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Where
- 2 sites in United States
- Volunteers
- 1,602 people
- Sponsor
- Bayer
Magnetic Resonance Angiography, Peripheral Vascular Diseases
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
The objective of the study was to compare the efficacy of Magnevist (SH L 451 A) at doses of 0.1 mmol/kg and 0.2 mmol/kg in contrast-enhanced 3D-Magnetic Resonance Angiography in three regions (abdominal, femoral, and leg…
- Conditions
- Magnetic Resonance Angiography, Peripheral Vascular Diseases, Peripheral Arterial Diseases
- Trial name
- NCT00652418
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Magnetic Resonance Imaging
Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose
The study was conducted to gain knowledge about a new dose of a diagnostic drug that is used for contrast-enhanced Magnetic Resonance Imaging (MRI) of the human central nervous system (CNS).
- Trial name
- LEADER 75 (NCT03602339)
- Testing
- Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Where
- 20 sites in United States, France and 5 more
- Volunteers
- 157 people
- Sponsor
- Bayer
Magnetic Resonance Imaging
A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
In this clinical study a contrast agent for magnetic resonance imaging (MRI), which has already been approved for application in adults, will be investigated in children and adolescents.
- Trial name
- NCT00468819
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 14 sites in Austria, Canada and 2 more
- Volunteers
- 140 people
- Sponsor
- Bayer
For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
The purpose of this study is to evaluate the efficacy and safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI); to explore the effective dose of HRS-9231 for CNS MRI; and to explore the population…
- Trial name
- NCT06731829
- Testing
- HRS-9231, Gadobutrol
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Magnetic Resonance Imaging
Contrast-enhanced MRI in Children 2 Months to <2 Years
The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to < 2 years of age
- Trial name
- NCT00937391
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-6661)
- Where
- 13 sites in United States, Germany
- Volunteers
- 54 people
- Sponsor
- Bayer
Contrast Enhancement in Magnetic Resonance Imaging, Healthy Volunteers
A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants
The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Japanese healthy male participants: the safety of BAY1747846 when given at increasing single doses…
- Trial name
- NCT06125366
- Testing
- BAY1747846
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Magnetic Resonance Imaging
Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
This is an open-label, multi-center study involving babies 0-2 months of age who have liver problems (pathology) and need to have their liver and possibly, the bile ducts imaged using magnetic resonance imaging and injection of a…
- Trial name
- NCT02084628
- Testing
- Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Diabetes Mellitus, Heart Failure
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular…
- Trial name
- NCT01440517
- Testing
- Tc99m-Maraciclatide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare